AstraZeneca PLC (AZN)
Automate Your Wheel Strategy on AZN
With Tiblio's Option Bot, you can configure your own wheel strategy including AZN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol AZN
- Rev/Share 17.7361
- Book/Share 13.2681
- PB 11.0029
- Debt/Equity 0.7625
- CurrentRatio 0.8974
- ROIC 0.1098
- MktCap 451602791086.0
- FreeCF/Share 2.9477
- PFCF 49.4203
- PE 58.0991
- Debt/Assets 0.2945
- DivYield 0.0211
- ROE 0.1918
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | AZN | Exane BNP Paribas | -- | Outperform | -- | $75 | April 15, 2025 |
| Upgrade | AZN | UBS | Neutral | Buy | -- | -- | Feb. 13, 2025 |
| Initiation | AZN | Morgan Stanley | -- | Overweight | -- | -- | Feb. 12, 2025 |
| Downgrade | AZN | Deutsche Bank | Hold | Sell | -- | -- | Sept. 13, 2024 |
News
Healthy Returns: Trump says major pharmaceutical tariffs coming ‘very shortly'
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Trump doubled down on plans to soon impose "major" pharmaceutical tariffs, while early stage startups dominated digital health funding deals in first quarter.
Read More
Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs
Published: April 09, 2025 by: WSJ
Sentiment: Negative
Drugmakers have said they're still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.
Read More
Pharmaceutical stocks fall as Trump doubles down on tariffs threat
Published: April 09, 2025 by: CNBC
Sentiment: Negative
Pharmaceutical stocks fell after President Donald Trump doubled down on plans to impose tariffs on pharmaceuticals imported into the U.S. "very shortly." Shares of Eli Lilly, AbbVie, Bristol Myers Squibb, Regeneron, Merck, Pfizer, Johnson & Johnson and Amgen, among others, all dropped on Wednesday.
Read More
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today
Published: April 09, 2025 by: The Motley Fool
Sentiment: Negative
Just like the rest of the stock market, pharmaceutical stocks are in a funk approaching the midweek mark, and it's looking like things might be about to get even worse for this particular pocket of the stock market. On Wednesday, Reuters reported that President Donald Trump is preparing to unveil a new series of tariffs on pharmaceutical imports.
Read More
AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
The European Commission approves AstraZeneca's Enhertu for a new breast cancer indication while also expanding Imfinzi label in lung cancer.
Read More
AstraZeneca and GSK shares rise on possible escape from new US tariffs
Published: April 03, 2025 by: Proactive Investors
Sentiment: Positive
UK pharmaceutical giants AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) shares both avoided the wider sell-off on Thursday morning on hopes that drug imports will escape the new 'reciprocal tariffs'. Based on a clarifying fact sheet produced by the White House alongside President Trump's announcement, it appears that pharmaceutical products imported into the US will be exempt from higher-rate tariffs "At least for now," says analyst Sean Conroy at Shore Capital.
Read More
AstraZeneca remains top pick with leading American bank. Here's why
Published: April 02, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN) has kept its spot as Bank of America's top pick in the pharmaceutical sector, with analysts raising their earnings forecasts and praising the company's “best-in-class” drug pipeline. The bank reiterated its 'buy' rating and lifted its price target to 14,500p, pointing to a 28% upside from current levels.
Read More
Healthy Returns: AstraZeneca cholesterol pill shows promise as race with Merck heats up
Published: April 01, 2025 by: CNBC
Sentiment: Positive
AstraZeneca's new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.
Read More
Brokers Suggest Investing in Astrazeneca (AZN): Read This Before Placing a Bet
Published: March 27, 2025 by: Zacks Investment Research
Sentiment: Negative
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca
Published: March 26, 2025 by: PRNewsWire
Sentiment: Neutral
AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC SEOUL, South Korea , March 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, will present a deep learning study on Epidermal Growth Factor Receptor (EGFR) mutation prediction in patients with non-small cell lung cancer (NSCLC) at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2025, held from April 25 to 30 in Chicago, Illinois. The study, which highlights the development and validation of the Lunit …
Read More
AstraZeneca and GKS shares have legs, but the weight loss titans will dominate, says investment bank
Published: March 24, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) remain among Berenberg's top picks in the pharmaceuticals sector, with the broker reaffirming its 'buy' rating on both stocks. The former carries a target price of £140, while the valuation for stock in the latter is £16.
Read More
Watch CNBC's full interview with AstraZeneca CEO Pascal Soriot
Published: March 21, 2025 by: CNBC International TV
Sentiment: Positive
Pascal Soriot, CEO of British pharmaceutical giant AstraZeneca, discusses the company's $2.5 billion investment in a new China research and development center.
Read More
Watch CNBC's full interview with Pascal Soriot, AstraZeneca CEO
Published: March 21, 2025 by: CNBC International TV
Sentiment: Positive
Pascal Soriot, CEO, AstraZeneca discusses the company's $2.5 billion investment in its new China research and development centre.
Read More
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
Published: March 19, 2025 by: Zacks Investment Research
Sentiment: Negative
The latest trading day saw Astrazeneca (AZN) settling at $76.32, representing a -0.97% change from its previous close.
Read More
AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
AstraZeneca is set to acquire EsoBiotec for $1 billion to develop in vivo cell therapies for multiple cancer indications or immune-mediated diseases.
Read More
AstraZeneca Stock Nears Buy Point After Long Run In Declining Market
Published: March 13, 2025 by: Investors Business Daily
Sentiment: Neutral
This biopharmaceutical stock is nearing a buy point of a cup-with-handle base. The post AstraZeneca Stock Nears Buy Point After Long Run In Declining Market appeared first on Investor's Business Daily.
Read More
AstraZeneca experimental blood pressure drug has a good shot of becoming a blockbuster
Published: March 12, 2025 by: Proactive Investors
Sentiment: Positive
UBS has reaffirmed its 'buy' rating on AstraZeneca PLC (LSE:AZN) with a 12-month price target of 14,200p, with the bank is optimistic about the potential of its blood pressure drug, baxdrostat. The Anglo-Swedish drugs giant is developing baxdrostat as part of a new class of treatments called aldosterone synthase inhibitors (ASIs).
Read More
BioInvent International AB: Year-End Report January 1 - December 31, 2024
Published: February 27, 2025 by: Accesswire
Sentiment: Neutral
LUND, SWEDEN / ACCESS Newswire / February 27, 2025 / BioInvent International (STO:BINV) "2024 was a year with several exciting developments reported from across our broad portfolio of clinical programs. We now have two Phase 2 and four Phase 1 trials running in our six clinical programs leveraging the TNFR2 and FcyRIIB targets.
Read More
AstraZeneca gets £2bn boost from breast cancer drug readout
Published: February 26, 2025 by: Proactive Investors
Sentiment: Positive
AstraZeneca PLC (LSE:AZN) has seen £2 billion added to its market value after reporting positive results from a breast cancer drug trial. The experimental treatment, camizestrant, improved patient survival without the disease worsening, according to an interim analysis.
Read More
AstraZeneca therapy improves survival in late-stage breast cancer trial
Published: February 26, 2025 by: Reuters
Sentiment: Positive
Pharmaceuticals major AstraZeneca said on Wednesday that its experimental treatment, camizestrant, improved survival in patients with an advanced form of breast cancer without the disease getting worse in a late-stage trial.
Read More
Final Trades: Starbucks, Astrazeneca, Western Union and the IYR
Published: February 25, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
AstraZeneca PLC Investors: Please contact the Portnoy Law Firm to recover your losses. February 21, 2025 Deadline to file Lead Plaintiff Motion
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
Investors can contact the law firm at no cost to learn more about recovering their losses
Read More
Leading Healthcare Institutions Adopt MSK-ACCESS® for Liquid Biopsy Testing
Published: February 24, 2025 by: PRNewsWire
Sentiment: Neutral
SOPHiA GENETICS enables institutions across the globe to launch world-class oncology testing BOSTON, MA and ROLLE, Switzerland, Feb. 24, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a pioneer in AI healthcare technology and a leader in data-driven medicine, announced a new milestone in the global adoption of its groundbreaking cancer testing applications MSK-ACCESS® powered with SOPHiA DDM™ and MSK-IMPACT® powered with SOPHiA DDM™. Thirty-seven prominent institutions, including top researchers and key opinion leaders worldwide, have already adopted the recently launched Liquid Biopsy and Solid Tumor applications.
Read More
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit - AZN
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131420&wire=1 or contact Joseph E. Levi, Esq.
Read More
AstraZeneca PLC Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights – AZN
Published: February 21, 2025 by: GlobeNewsWire
Sentiment: Neutral
NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit.
Read More
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in AstraZeneca PLC. of Class Action Lawsuit and Upcoming Deadlines - AZN
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Read More
Levi & Korsinsky Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZN
Published: February 21, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131175&wire=1 or contact Joseph E. Levi, Esq.
Read More
Lost Money on AstraZeneca PLC(AZN)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ: AZN) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AstraZeneca investors who were adversely affected by alleged securities fraud between February 23, 2022 and December 17, 2024.
Read More
AZN Deadline: AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit Filed by The Rosen Law Firm
Published: February 21, 2025 by: PRNewsWire
Sentiment: Neutral
NEW YORK , Feb. 21, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AstraZeneca PLC (NASDAQ: AZN) between February 23, 2022 and December 17, 2024, both dates inclusive (the "Class Period"), of the February 21, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. So what: If you purchased AstraZeneca securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Read More
Levi & Korsinsky Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming Deadline - AZN
Published: February 20, 2025 by: Accesswire
Sentiment: Neutral
NEW YORK, NY / ACCESS Newswire / February 20, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/astrazeneca-plc-lawsuit-submission-form?prid=131097&wire=1 or contact Joseph E. Levi, Esq.
Read More
About AstraZeneca PLC (AZN)
- IPO Date 1993-05-12
- Website https://www.astrazeneca.com
- Industry Drug Manufacturers - General
- CEO Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.
- Employees 94300